Ben Stevens
Ben is the editor of Business of Cannabis. Since 2021, he has researched, written, and published the vast majority of the outlet’s content, delivering agenda-setting journalism on regulation, business strategy, and policy across Europe.
Ben Stevens · page 115
- CBD Market
‘Landmark’ Ruling Gives Hope For UK CBD Flower Businesses
A ‘landmark’ Court of Appeal ruling in the UK has set a new legal precedent for businesses in the UK importing and selling CBD or low-THC hemp flower.
- Uncategorized
SAFE Banking Act Unlikely To See Vote Ahead Of Summer Recess
The Secure and Fair Enforcement (SAFE) Banking Act may now not be voted on before the summer recess, extinguishing its proponents’ hopes it could get a markup next week.
- Opinion
The Growing Need for Medicinal Cannabis is a Reality in Spain That Cannot be Avoided
Ahead of the snap Spanish election this weekend, Chief Executive Officer of Linneo Health Don Bellamy lays out the frustrating situation for thousands of patients who are forced to turn to the black market despite a medical cannabis framework being ‘within reach’.
- Uncategorized
Missouri Will Conduct Marijuana Business Demographic Survey Amid Criticism That Black People Are Being Left Out Of Industry
State officials in Missouri have pledged to launch a demographics survey of cannabis business owners for the first time in a move aimed at addressing criticisms of underrepresentation of the Black community.
- Uncategorized
New Jersey Cannabis Regulators Significantly Roll Back Plans to Prioritise Social Equity Licensees for a Year
In a shock move, New Jersey regulators have significantly amended plans to give ‘social equity’ applicants the first shot at establishing cannabis businesses.
- Markets & Stocks
OCT Announces Potential New ‘First In Class’ Immunotherapy Treatment, Kanabo Stock Jumps On New Deal, Intercure Leaves TSX
Oxford Cannabinoid Technologies [stock_market_widget type=”chart” template=”basic” color=”#5679FF” assets=”OCTP.L” range=”1mo” interval=”1d” axes=”true” cursor=”true” range_selector=”true” display_currency_symbol=”true” api=”yf”] Oxford Cannabinoid Technologies announced this week that it had identified a potential ‘first in class’ immunotherapy treatment for solid tumours.
- Companies
Akanda Corp Faces Delisting For 2nd Time After Stock Consolidation
AKANDA Corp is under threat of being delisted from NASDAQ for the second time in less than a year, throwing its future as a publicly listed company into question.
- Uncategorized
Trulieve Files Lawsuit to Recover $24m From Former Partners
US cannabis giant Trulieve has filed a civil lawsuit against its former business partners in a bid to recover unpaid debts worth nearly $25m.
- Uncategorized
Organigram Blames ‘THC Inflation’ For Growing Losses and Falling Revenues in Q3
Canadian cannabis cultivator Organigram Holdings published its Q3 earnings last week, reporting falling revenues and a net loss of $213.5m.
- Press releases
Prescribing Medical Cannabis Can Drive Down NHS Waiting Times Says New CIC Report
Allowing GPs to prescribe medical cannabis can drive down NHS waiting lists and reduce crime, according to a new report from the Cannabis Industry Council (CIC).
- Press releases
Oxford Cannabinoid Technologies Announces Expansion Into Oncology
OCTP, the pharmaceutical company developing prescription cannabinoid medicines, is formally expanding its research and development strategy into oncology having identified a potential “first in class” immunotherapy agent for the treatment of solid tumours.
- Uncategorized
Canopy Growth Signs Deal To Reduce Debt by $437m, But Concerns Remain Over Financial Future
Canadian cannabis giant Canopy Growth announced of Friday that it has reached an agreement with its lenders to significantly reduce its debt.










